Clinical Trials Sponsored by Neurex

Total 332 results

Neuren Pharmaceuticals Limited

Suspended

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Prader-Willi Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Fragile X Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Female Subjects

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC (INTREPID2566)

Brain Injuries

United States
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury (INTREPID2566)

Brain Injuries

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Neuren Pharmaceuticals Limited

Terminated

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Concussion

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited
rettsyndrome.org

Completed

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Rett Syndrome

United States
Neurex

Completed

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

HIV Infections | Pain | Cancer

United States
Neuron, Spain

Recruiting

rTMS Over S1 Enhance Motor Learning in Healthy People

Transcranial Magnetic Stimulation | Motor Learning

Spain
Neurent Medical

Recruiting

NEUROMARK Randomized Controlled Trial

Chronic Rhinitis

United States
Neurent Medical

Recruiting

NEUROMARK Registry Study

Chronic Rhinitis

United States
NeuroRx, Inc.

Recruiting

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 (AVICOVID-2)

SARS-CoV 2 | COVID | ARDS | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Dyspnea | ALI

United States
Naturex-Dbs

Unknown

Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)

Lower Urinary Tract Symptoms
NeuroDx Development

Withdrawn

Multi-Center Study of ShuntCheck

Blocked Ventricular Shunts
Fondazione Neureca

Unknown

Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale (IRIS)

Parkinson's Disease

Italy
Neurent Medical

Completed

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)

Chronic Rhinitis

United States
Neurop Inc.

Completed

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Safety Issues

United States
NeuroRx, Inc.

Not yet recruiting

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Neuron, Spain

Recruiting

Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients

Stroke | Gait Disorders, Neurologic | Walking

Spain
Neurent Medical

Completed

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (MERIDIEN)

Chronic Rhinitis

United States
Neurent Medical

Active, not recruiting

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

Chronic Rhinitis

United States
NeuTec Pharma

Completed

Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer

Cancer of the Breast

Poland, Serbia
NeuTec Pharma

Completed

Aurograb and Vancomycin in MRSA Infection

Staphylococcal Infections

United Kingdom
Nurea

Withdrawn

Comparative Study of a Software With the Gold Standard

Abdominal Aortic Aneurysm (AAA)

France
Nurea

Completed

Validation of a Software and the Follow-up of Anteropoterior Migration of Stent (ASMOT)

Aortic Aneurysm

France
Neuro+

Completed

Efficacy of Neuro+ Attention Training

ADHD

United States
Neurim Pharmaceuticals Ltd.

Completed

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Alzheimer's Disease

United States
Neurim Pharmaceuticals Ltd.

Completed

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Primary Insomnia

United States
Neurim Pharmaceuticals Ltd.

Completed

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Sleep Disorder | Alzheimer's Disease

United States, United Kingdom, Israel
Neurim Pharmaceuticals Ltd.

Terminated

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

Levodopa-induced Dyskinesia

Israel
Neurim Pharmaceuticals Ltd.

Completed

Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects

Postural Instability

France
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Sleep Disorders

United States, Netherlands, United Kingdom, Finland, France
Neurim Pharmaceuticals Ltd.

Withdrawn

Efficacy and Safety of Slenyto for Insomnia in Children With ASD (ASD)

Autism Spectrum Disorder
Naturex SA
BioFortis

Completed

A Clinical Trial to Evaluate the Chronic Safety and Tolerance of Turmipure Gold™ in Healthy Subjects (TURBIO-GOLD)

Liver Function | Gastrointestinal Tolerance | Kidney Function

France
Laval University
Naturex

Completed

Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome (MICA)

Overweight | Metabolic Syndrome | Insulin Resistance | Endotoxemia | Microbiota

Canada
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Primary Insomnia

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs (Neu I)

Primary Insomnia

France
Neuros Medical, Inc.

Active, not recruiting

Electrical Nerve Block for Amputation Pain

Phantom Limb Pain | Residual Limb Pain | Post-Amputation Pain | Stump Pain

United States
Northumbria University
Naturex

Completed

To Assess the Influence of Aronox on Parameters Associated With Aerobic Performance

Aerobic Capacity

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Sleep Problems

Netherlands
Neurim Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia

Insomnia

France
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Blindness | Non-24 Hour Sleep-Wake Disorder

United States
Neurim Pharmaceuticals Ltd.

Completed

A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

Diabetes Mellitus, Type 2 | Insomnia
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Slovakia, Poland, Hungary, Japan, Russian Federation
Naurex, Inc, an affiliate of Allergan plc

Completed

Assessment of Abuse Potential of Rapastinel in Humans

Human Abuse Potential

United States

3

Subscribe